Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
These early DRAGON findings of safety, target engagement and indications of efficacy support our conviction around Scholar Rocks differentiated approach and the potential role that SRK-181 may play in addressing the existing treatment hurdles.
- These early DRAGON findings of safety, target engagement and indications of efficacy support our conviction around Scholar Rocks differentiated approach and the potential role that SRK-181 may play in addressing the existing treatment hurdles.
- We are excited to continue advancing DRAGON and look forward to sharing additional data next year.
- The biomarker strategy for DRAGON explores early signs of SRK-181 activity, including target engagement and pathway modulation.
- The DRAGON Phase 1 proof-of-concept clinical trial (NCT04291079) in patients with locally advanced or metastatic solid tumors is ongoing.